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Abstract
Background: We evaluated prospectively the predic-
tive value of serum apolipoprotein (apo) A-II, the
second major apolipoprotein of high-density lipopro-
tein (HDL), for cardiometabolic risk in Turkish adults
showing abnormalities in other proteins that normally
confer protection.
Methods: Determinants of apoA-II and its associations
with coronary heart disease (CHD), metabolic syn-
drome (MetS) and diabetes were investigated at 4
years follow-up in 193 elderly men and women.
Results: ApoA-II concentrations at baseline, in addi-
tion to being significantly related to HDL-cholesterol,
were directly associated with complement C3 in mul-
tivariate linear regression analyses comprising nine
variables. Following adjustment for gender, age and
HDL-cholesterol ()30/)33 g/L, in men and women,
respectively), low serum apoA-II concentrations pre-
dicted incident MetS wrelative risk (RR) 3.5 (95% CI 1.4;
8.6)x and type 2 diabetes wRR 4.5 (95% CI 1.3; 15.6)x in
both genders at an increment of 1 SD. Increased
apoA-II values were not associated with prevalent or
incident CHD, and tended to be marginally atheropro-
tective only in males.
Conclusions: Serum apoA-II concentrations confer
risk for MetS and diabetes and exhibit evidence of
anti-inflammatory properties among Turks. These
findings support the effects seen for several other
HDL protein constituents. This finding may explain
the increased cardiometabolic risk among Turks.
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Introduction
Apolipoprotein (apo) A-II is the second most common
protein constituent of high-density lipoprotein (HDL),
comprising 20% of the HDL protein (1). Studies in
apoA-II transgenic mice indicate that apoA-II regu-
lates the metabolism of triglyceride-rich lipoproteins
(TRL), being transferred to TRLs from the HDL protein
stores (2). In apoA-II transgenic mice, human apoA-II
is reabsorbed in kidney proximal tubules in relation
to its plasma concentration, and then degraded (3). In
animals expressing human apoA-II carried by very
low-density lipoprotein (LDL), the association of
human apoA-II with TRL induces postprandial hyper-
triglyceridemia due to inhibition of lipoprotein lipase
and hepatic lipase activities (4).
ApoA-II has been suggested in some studies to
have poor antiatherogenic or even proatherogenic
properties (5, 6). High lipoprotein A-I (LpA-I), but not
LpA-I/A-II concentrations, were associated with a
more favorable metabolic risk profile in the HERI-
TAGE Family study (7). In patients with coronary
artery disease, apoA-II concentrations were found to
be low-normal (8) or high (in interstitial fluid) (9) in
different studies. But apoA-II was shown in a recent
prospective, large nested case-control analysis, the
EPIC-Norfolk study, to be associated with a decreased
risk of coronary disease (ORs0.48 upper vs. lowest
quartile, 95% CI 0.34; 0.67) in apparently healthy sub-
jects. This finding implied that there are effects from
apoA-II on specific antiatherogenic pathways (10). The
authors believed that arguments for a potential pro-
atherogenic effect of apoA-II were no longer valid.
Apparent cardioprotection was shown by APOAII
rs5082 polymorphism in another case-control analy-
sis of nearly 1000 Australian men (11): the CC geno-
type exhibited lower risk of coronary artery disease
(ORs0.57, ps0.004) compared with T allele carriers.
The question of whether apoA-II concentrations in
humans are involved in protecting against risk of
metabolic disorders has not been adequately investi-
gated (12, 13). In a previous cross-sectional analysis
of an elderly sample from the Turkish Adult Risk Fac-
tor (TARF) study, using logistic regression analyses,
gender- and age-adjusted apoA-II concentrations
were not shown to be associated with coronary heart
disease (CHD), metabolic syndrome (MetS) or type 2
diabetes (14). However, recent prospective analyses
in the TARF showed that increased serum apo A-I was
diabetogenic and tended to be atherogenic among
Turks (15). In addition, increased concentrations of
adiponectin (16), HDL-cholesterol (17) and apoC-III in
HDL (18) showed similar effects. The abnormal func-
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tions of these normally protective serum proteins
have been proposed to result from an environment of
atherogenic dyslipidemia, excessive oxidative stress
and systemic low-grade inflammation associated with
the high prevalence of MetS among Turks (19).
Our goal was to investigate whether apoA-II is con-
tributory to the prediction of development of MetS,
diabetes and CHD in males and females using follow-
up data from a sample population. In the event of a
pro-inflammatory effect, the independence of this
association from that of HDL-cholesterol levels, dem-
onstrated in the TARF study (17), was investigated.
Subjects and methods
Subjects
Due to economic constraints, the study sample consisted
of randomly selected elderly participants of the TARF study
(20). Selection was based primarily on age and those likely
to be at high cardiometabolic risk. The study sample con-
sisted of individuals reported previously in a cross-sectional
study of serum apoA-II (measured in 2003) (14). Participants
were 35–80 years of age at baseline and were residents from
regions of Central Anatolia and Marmara. The study was
approved by the Ethics Committee of the Istanbul University
Medical Faculty. Written informed consent was obtained
from all participants.
Waist circumference was measured midway between the
lower rib margin and the iliac crest with the subject standing
at the end of expiration. Cigarette smoking status was cate-
gorized into current smokers, former smokers and those that
never smoked. Individuals taking alcohol once a month or
more were considered to be users of alcohol. Blood pressure
was measured in the sitting position using the right arm
with an aneroid sphygmomanometer (Erka, Bad To¨lz, Ger-
many), after at least 5 min of rest. The mean of two record-
ings, taken 3 min apart, was used. Physical activity was
graded into one of four categories (20). Lipid lowering drugs
were used by six participants, hormone replacement therapy
in three.
Blood samples were collected following 11 h or more of
fasting in 91% of individuals. Samples were shipped on
cooled gel packs to Istanbul to be stored at –758C, until anal-
ysis at the Yıldız Technical University. Serum concentrations
of apoA-II, A-I and B, complement C3 and C-reactive protein
(CRP) were measured using nephelometry (BN Prospec, Beh-
ring Diagnostics, Westwood, MA, USA). The intraassay CV
for apoA-II with both was 1.4% and the interassay CV was
5.5%. Serum concentrations of total cholesterol, fasting tri-
glycerides, glucose, and HDL-cholesterol (directly without
precipitation) were determined by using enzymatic kits from
Roche Diagnostics with a Hitachi 902 autoanalyzer (Roche
Diagnostics, Mannheim, Germany). Serum phospholipid
measurements were performed colorimetrically with
WAKO’s phospholipids B kits. Insulin concentrations were
determined by the chemiluminescent immunometric meth-
od using reagents from Roche and the Elecsys 1010
immunoanalyzer.
Definitions and outcomes
Diabetes was diagnosed using criteria of the American
Diabetes Association (21), a fasting plasma glucose G7.0
mmol/L (or 2-h postprandial glucose )11.1 mmol/L) and/or
the current use of diabetes medication. Individuals with
MetS were identified when three of five criteria of the
National Cholesterol Education Program (ATP III) (22) were
met, modified for prediabetes (fasting glucose 5.56–
6.99 mmol/L (23) and further for abdominal obesity using as
cut point G95 cm in men, as recently assessed in the TARF
study (24).
Diagnosis of non-fatal CHD was based on the presence
of angina pectoris, a history of myocardial infarction with
or without accompanying Minnesota codes of the ECG (25),
or on a history of myocardial revascularization. Typical angi-
na and, in women, an age )45 years was a prerequisite for
diagnosis when angina was isolated. ECG changes of ‘‘ische-
mic type’’ of greater than minor degree (Codes 1.1–2, 4.1–2,
5.1–2, 7.1) were considered as myocardial infarct sequelae
or myocardial ischemia. CHD death comprised fatal coronary
event and death from heart failure of coronary origin.
Exclusion and follow-up Of the 102 men and 91 women
comprising the sample, patients with prevalent CHD, MetS
and diabetes were excluded in the analysis of respective inci-
dent outcomes. Participants were monitored for 4 years,
from 2003 when apoA-II was measured until 2007.
Data analysis
Descriptive parameters were evaluated as means"standard
deviation (SD) or percentages. Two-sided t-tests and Pear-
son’s x2-tests were used to analyze the differences in means
and proportions between groups. Pearson correlations were
used for continuous and Spearman correlations for categor-
ical or log-transformed variables. Linear regression analysis
was performed with apoA-II as the dependent variable. Esti-
mates (and 95% confidence intervals) for relative risk (RR) of
a dependent variable were determined by use of logistic
regression analyses in models that controlled for gender,
age and serum HDL-cholesterol. With respect to CHD risk,
confounders, such as smoking status, alcohol use and lipid
lowering drugs were included. ApoA-II concentrations were
divided into gender-specific high (in rounded figures )0.30/
)0.33 g/L in men and women, respectively) and low apoA-
II concentrations. The cut-off threshold represented the 47th
percentile in each sex. RRs were expressed in terms of incre-
ments of 1 SD of apoA-II (0.061 g/L), or other variables. The
gradient across high and low mean apoA-II values corre-
sponded to 1.3 SD. This value was used as the exponent to
calculate and express the RRs in terms of 1 SD increment. A
value of p-0.05 on the two-sided test was considered sta-
tistically significant. Statistical analyses were performed
using SPSS-10 for Windows (SPSS Inc., Chicago, IL, USA,
Nr. 9026510).
Results
At baseline, MetS was present in 85 (56%), diabetes
in 36 (19%) and CHD in 51 (26%) patients. Total follow-
up consisted of 637 (mean 3.30) person-years during
which 18 incident CHD, 25 MetS and 13 type 2 cases
of diabetes developed.
Clinical characteristics of the sample population
(mean age 63"10 years) at baseline are shown in
Table 1, according to gender. Participants were gen-
erally (abdominally) obese; women exhibited a ten-
dency for hypertension, increased concentrations of
LDL-cholesterol, fasting triglycerides, complement C3
and fibrinogen. These tendencies in females have
been observed, albeit to a lesser extent, in the entire
TARF cohort. Several variables were measured on a
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Table 1 Baseline characteristics of the study sample (ns193).
Men Women
n Mean SD n Mean SD
ApoA-II, g/L 102 0.304 0.04 91 0.337 0.07
Age, years 102 63.4 11.2 91 62.8 9.4
Waist circumference, cm 102 97.9 12.7 91 96.7 11.2
Body mass index, kg/m2 102 28.4 4.9 91 31.9 5.6
Systolic blood pressure, mmHg 102 137.0 19.4 91 143.9 20.4
Diastolic blood pressure, mmHg 103 84.1 10.9 91 85.6 9.4
Total cholesterol, mmol/L 102 4.89 0.92 91 5.79 1.09
HDL-cholesterol, mmol/L 102 1.02 0.27 91 1.26 0.39
LDL-cholesterol, mmol/L 91 3.05 0.79 91 3.67 0.88
Fasting triglycerides, mmol/L 91 1.75 0.96 84 1.88 0.88
Total phospholipids, mg/dL 44 188.4 34.9 39 216.3 33.3
Fasting glucose, mmol/L 83 5.8 1.97 75 5.9 2.25
Fasting insulina, mIU/L 75 7.94 1.8 77 9.11 1.7
Apolipoprotein A-I, g/L 79 1.30 0.20 70 1.54 0.29
Apolipoprotein B, g/L 55 1.12 0.31 60 1.29 0.56
Complement C3, g/L 59 1.29 0.26 64 1.39 0.24
C-reactive proteina, mg/L 99 2.3 3.6 85 3.1 2.8
Uric acid, mmol/L 70 345 71 60 298 95
Current/former smokers, n % 102 35/39 34/37 91 11/4 12.1/4.4
Alcohol use, % 102 12.6 91 0
aLog-transformed values.
Table 2 Correlations of serum apoA-II with risk parameters, by gender.
Men ns102 Women ns91
n r p-Value n r p-Value
Phospholipidsa, mg/dL 43 0.63 -0.001 39 0.60 -0.001
ApoA-Ia, g/L 79 0.30 0.008 70 0.19 0.12
HDL-cholesterol, mmol/L 102 0.38 -0.001 91 0.29 0.005
Total cholesterol, mmol/L 102 0.42 -0.001 91 0.10 0.36
Complement C3, g/L 58 0.36 0.005 66 0.16 0.21
Triglyceridesa, mmol/L 91 0.34 -0.001 84 0.04 0.71
LDL-cholesterol, mmol/L 100 0.24 0.017 86 –0.01 0.93
Body mass indexa, kg/m2 102 0.15 0.14 91 –0.03 0.81
Smoking statusa 102 –0.08 0.42 91 –0.10 0.34
Agea, years 102 –0.25 0.012 91 –0.06 0.58
Uric acid, mmol/L 70 0.15 0.21 60 –0.20 0.13
Fasting glucosea, mmol/L 83 0.13 0.23 75 0.03 0.78
Fasting insulinb, mIU/L 74 0.13 0.26 77 –0.11 0.36
C-reactive proteinb, mg/L 98 –0.07 0.49 85 –0.06 0.58
aSpearman tests, bLog-transformed values. Bold numbers highlight significant values.
subset of participants, but logistic regression analyses
were not significantly affected by these limitations.
Relationship of apoA-II with other risk parameters
Correlation between apoA-II and selected parameters
are shown in Table 2. The strongest correlation (r
0.34–0.63) was seen with serum phospholipids, apo-
A-I, HDL- and total cholesterol, complement C3 and
triglycerides. This was much weaker in women. Male
age showed an inverse correlation.
Linear regression models for each gender using
covariates of apoA-II comprising nine variables con-
sidered to be related to a pro-inflammatory state
(age, smoking status, alcohol use, level of physical
activity, waist circumference, systolic blood pressure,
and log CRP, complement C3 and HDL-cholesterol)
explained the high apoA-II variance in men. In con-
trast, the model as a whole did not significantly
explain the apoA-II variance in women (ps0.26). HDL-
cholesterol was significantly associated with apoA-II
in both genders, but only age and complement C3
showed significant association in men (Table 3).
Results of logistic regression analyses of high
()0.30/)0.33 g/L) vs. low apoA-II concentrations for
incident MetS or type 2 diabetes are given in Table 4.
After adjustment for gender, age and HDL-cholesterol,
a 1 SD-increment in apoA-II values predicted MetS
significantly in both males and females with an RR of
3.5 (95% CI 1.4; 8.6). Diabetes was also predicted by
high apoA-II concentrations, showing RR of 4.5 (95%
CI 1.3; 15.6) at an increment of 1 SD. RRs in either
gender, although higher in females, did not attain sig-
nificance due to the low number of events.
Table 5 shows the logistic regression analyses of
high vs. low apoA-II concentrations for incident CHD
or for an endpoint of combined prevalent and incident
CHD, after adjustments for gender, age, HDL-choles-
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Table 3 Multivariable linear regression for covariates of serum apoA-II, by gender (ns116).
Men ns57 Women ns59
b-Coefficient SE p-Value b-Coefficient SE p-Value
Age, decade –1.4 0.5 0.009 –0.6 1.6 0.72
Complement C3, 0.25 g/L 2.6 0.5 -0.001 1.8 1.4 0.19
HDL-cholesterol, 0.31 mmol/L 3.7 0.5 -0.001 2.3 0.9 0.014
Current vs. never smoked –0.5 1.0 0.63 –6.0 4.0 0.14
Waist circumference, 11 cm –0.4 0.4 0.37 0.3 1.3 0.81
C-reactive proteina, mg/L, 3-fold –0.23 0.21 0.29 2.2 1.6 0.19
ApoA-II variance r2s0.61, pF0.001 r2s0.1, ps0.26
aLog-transformed. Model adjusted also for systolic blood pressure, physical activity grade, alcohol use (all p)0.3). Bold
numbers highlight significant values.
Table 4 Logistic regression analysis of high vs. low apoA-II concentrations for incident metabolic syndrome (MetS) and type
2 diabetes.
RR 95% CI RR 95% CI RR 95% CI
Incident MetS Total, ns25/85c Men, ns16/56 Women, ns9/29
Gender, female 1.89 0.52; 6.88
Age, 5 years 1.09 0.86; 1.38 0.93 0.67; 1.23 1.95 1.02; 3.76
ApoA-II, )0.30/)0.33 g/L vs. lowa 3.5 1.4; 8.6 2.8 0.91; 8.6 9.8 0.87; 111
HDL-cholesterolb, 0.31 mmol/L 0.51 0.27; 0.95 0.37 0.12; 1.14 0.49 0.19; 1.27
Incident diabetes Total, ns13/157c Men, ns9/82 Women, ns4/75
Gender, female 0.96 0.24; 3.9
Age, 5 years 0.88 0.66; 1.18 0.80 0.57; 1.14 0.94 0.54; 1.63
ApoA-II, )0.30/)0.33 g/L vs. lowa 4.5 1.3; 15.6 2.09 0.59; 7.45 3.6 0.55; 23.6
HDL-cholesterolb, 0.31 mmol/L 0.42 0.17; 1.06 0.56 0.17; 1.86 0.39 0.10; 1.56
aExpressed in terms of 1 SD increment in apoA-II, bhas to be inversely related to MetS by selection according to definition,
cnumber of new events/number at risk in model. Bold numbers highlight significant values.
Table 5 Logistic regression analysis of multi-adjusted high vs. low apoA-II concentrations for prevalent and incident coronary
heart disease (CHD).
RR 95% CI RR 95% CI RR 95% CI
Incident CHD Total, ns18/142b Men, ns12/74 Women, ns6/68
ApoA-II, )0.30/)0.33 g/La 0.68 0.29; 1.63 0.57 0.10; 3.14 1.12 0.27; 4.68
HDL-cholesterol, 0.31 mmol/L 0.49 0.23; 1.09 0.49 0.18; 1.41 0.43 0.12; 1.49
Prevalent and incident CHD Total, ns67/191b Men, ns39/101 Women, ns29/91
ApoA-II, )0.30/)0.33 g/La 0.94 0.53; 1.65 0.74 0.31; 1.82 1.07 0.48; 2.37
HDL-cholesterol, 0.31 mmol/L 0.70 0.48; 1.02 0.69 0.36; 1.28 0.69 0.44; 1.13
Current vs. never smoked 0.60 0.23; 1.56 0.92 0.29; 2.91 0.57 0.05; 6.20
Adjusted also for age and lipid lowering drugs (both p-0.05), gender and alcohol usage (both p)0.05). aExpressed in terms
of 1 SD increment in apoA-II, bnumber of new events/number at risk in model. Values in italic font type denote borderline
significance.
terol, smoking status, alcohol use and lipid lowering
drugs. RRs for high apoA-II were below unity wRR 0.74
(95% CI 0.31; 1.82)x in men, but above unity in women
wRR 1.07 (95% CI 0.48; 2.37)x for a 1 SD increment,
without approaching significance. Findings appeared
to be similar in the analyses for incident CHD.
Discussion
The present prospective study on an elderly Turkish
adult population showed evidence of anti-inflamma-
tory abnormalities associated with serum apoA-II con-
centrations. These results confirmed similar abnormal
function for serum HDL and its other protein constit-
uents (apoA-I and apoC-III) in a large number of Turks.
After adjustments for HDL-cholesterol and other con-
founders, high serum apoA-II concentrations predict-
ed MetS and diabetes in all individuals comparedwith
low apoA-II concentrations, implicating pro-inflam-
matory activity of this protein. However, high serum
apoA-II tended to be marginally protective against
CHD in men.
Comparative age-specific data on apoA-II concen-
trations are scarce. Values averaged 0.32 ("0.007
SEM) g/L in middle-aged Mexican-Americans (26),
similar to those in the current study. Values were sub-
stantially higher in the PROCAM study, ranging
between 39.5–41.9 and 43.0–45.0 mg/dL in 15–64-
year-old men and women, respectively (27).
It must be considered that most participants had
abdominal obesity, with combined hyperlipidemia,
hypertension, and usually with increased concentra-
tions of acute phase reactants, such as complement
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C3 and fibrinogen, particularly in women. ApoA-II
has been linked to combined hyperlipidemia. Ribas
et al. (28) studied the ability of HDL to protect against
oxidative modification of apoB-containing lipopro-
teins in mice. They found that incubation of isolated
human apoA-II with mouse control plasma decreased
paraoxonase activity and displaced the enzyme from
HDL; thus overexpression of human apoA-II in mice
impaired the normally protective ability of this
protein.
Manifestations of impaired anti-inflammatory/
anti-oxidative activities of apoA-II
At odds with the anticipated positive anti-inflamma-
tory activities of apoA-II particles, our population
showed evidence for impaired anti-inflammatory
activity. This was observed in baseline apoA-II con-
centrations with several variables representing
enhanced systemic inflammation, such as correlation
with body mass index, serum triglycerides, LDL-cho-
lesterol, apoA-I wdemonstrated to possess adverse
properties (15, 17)x and being linearly related to com-
plement C3. The finding of weaker correlations in
females compared with males may be related to pro-
inflammatory/pro-oxidant state having greater impact
on cardiometabolic risk in Turkish women. Conse-
quently, inflammation-related factors do not show
significant independence. In addition, the develop-
ment of MetS and diabetes was predicted by apoA-II
concentrations, irrespective of HDL-cholesterol con-
centrations. This phenomenon is consistent with pre-
viously demonstrated cardiometabolic risk conferred
by similar functional alterations in HDL (17), apoA-I
(15), apoC-III in HDL (18) and in adiponectin (29) in the
TARF cohort.
In transgenic mice, the human APOAII gene was
stimulated by high carbohydrate intake following fast-
ing. In mice that overexpressed this gene, plasma
apoA-II concentrations were positively correlated with
blood glucose concentrations. It was hypothesized
that, in type 2 diabetes, increased apoA-II causes an
increase in plasma triglycerides and glucose intoler-
ance. This results in hyperglycemia, which in turn
might increase APOAII gene transcription (30).
Analyses showed that HDL cholesterol concentra-
tions helped protect against the outcomes of diabetes
and CHD. This suggests that, when controlled for
apoA-II, HDL particles largely retained both anti-
inflammatory and anti-atherogenic activities. It is con-
sidered that a pro-inflammatory state/oxidative stress,
closely linked to the highly prevalent MetS in this
population sample, is the main reason for an impaired
protective function of apoA-II (and other proteins) by
involvement of specific enzymes. Increased CHD risk
in South Asian immigrants have been ascribed to sim-
ilar HDL dysfunction involving its apolipoproteins
(31).
Our findings are consistent with a view that sepa-
rate apos on HDL may display specific dysfunction,
which may be associated with impairment of reverse
cholesterol transport of HDL particles. It appears that
impaired apoA-II function is commonly associated
with an increase in apoA-II concentrations. This might
be related to reduced catabolism of apoA-II which has
been observed following the use of torcetrapib (32).
Limitations of the study include the small sample
size, thus requiring caution in interpreting our find-
ings until confirmed in other studies. However, the
study sample allowed us to elicit the significant rela-
tionships with other inflammatory markers and devel-
opment of MetS and diabetes. These observations
are consistent with previous findings regarding other
cardioprotective proteins. The applicability of the
present findings to populations with a much lower
prevalence of MetS and diabetes remains to be stud-
ied. The prospective design and the inclusion of both
male and female subjects are strengths of the study.
Conclusions
High serum apoA-II concentrations do not protect, but
rather predict the development of MetS and type 2
diabetes in Turks. It can be inferred that apolipopro-
teins may have inherent proinflammatory activities,
presumably in populations with a high prevalence of
MetS. These findings contribute to excess cardiomet-
abolic risk among Turks.
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